Selected Publications

Here you will find an overview of our research group's selected publications over several years.

  • Ali M, Foldvari Z, Giannakopoulou E, Böschen ML, Strønen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN, Olweus J. Induction Of Neoantigen Reactive T Cells From Healthy Donors. Nature Protocols (2019) 14, 1926-1943.
    Here we provide a protocol for high-throughput discovery of neo-antigen reactive T cells and their targets for adoptive T cell therapy and vaccine design.
  • Strønen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Böschen ML, Lund-Johansen F, Olweus J*, Schumacher TN*. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science (2016)  352 (6291), 1337-1341 *Shared senior and corresponding authors.
    doi: 10.1126/science.aaf2288
    We show that healthy donor T cells can recognize 5-fold more mutations than tumor-infiltrating T cells from the patient, and that donor T-cell receptors can mediate efficient and specific killing of patient tumor cells harboring the relevant mutations.
    Commentaries: Science. 2016;352(6291):1275-1276, and
    N Engl J Med. 2017;376(5):491-493, and in Mol Ther 2016 Aug;24(7):1170-3
  • Liaskou E, Klemsdal Henriksen EK, Holm K, Kaveh F, Hamm D, Fear J, Viken MK, Hov JR, Melum E, Robins H, Olweus J*, Karlsen TH, Hirschfield GM*. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. Hepatology 63, 1608-1619 (2016) *Corresponding author
    2016 May;63(5):1608-19.
    doi: 10.1002/hep.28116
    We identify liver-infiltrating, disease-associated T cell clonotypes in two autoimmune liver diseases and in alcoholic liver disease, and evidence for antigen-driven clonal expansions.
  • Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 2015;125:82-89. Doi: 10.1182/blood-2014-07-592162.
    We demonstrate that the magnitude of anti-tumor CD8 T cell responses correlate with clinical responses to a novel immunotherapy
    Commentary in Blood 2015; 125(5) 5-7
  • Olweus J. Manufacture of CAR-T cells in the body. News and Views article
    Nat Biotechnol. 2017 Jun 7;35(6):520-521.
    doi: 10.1038/nbt.3898.
  • Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Walchli S, Olweus J. Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. Oncoimmunology 2016 Feb 18;5(5):e1138199.
    doi: 10.1016/j.jhep.2016.09.002.
  • Taraldsrud E, Fevang B, Jorgensen SF, Moltu K, Hilden V, Tasken K, Aukrust P, Myklebust JH, Olweus J. Defective IL-4 signaling in T cells defines severe common variable immunodeficiency. J Autoimmun 2017 Jul;81:110-119.
    doi: 10.1016/j.jaut.2017.04.004. 
  • Kumari S, Walchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci U S A 111, 403-408 (2014)
    doi: 10.1073/pnas.1306549111.
    Faculty of 1000 Prime: http://f1000.com/prime/718206020?bd=1(Two stars)
  • Abrahamsen IW, Stronen E, Wälchli S, Johansen JN, Kjellevoll S, Kumari S, Komada M, Gaudernack G, Tjonnfjord G, Toebes M, Schumacher TN, Lund-Johansen F, Olweus J.
    Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia. 2010 Nov;24(11):1901-9.
    doi: 10.1038/leu.2010.186.
  • Kvale EØ, Dalgaard J, Lund-Johansen F, Rollag H, Farkas L, Midtvedt K, Jahnsen FL, Brinchmann JE, Olweus J. Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells.
    Blood, 109 (8), 3369-76
    doi: 10.1182/blood-2006-06-031484
  • Ali, M., Giannakopoulou, E., Li, Y. et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nat Biotechnol (2021).https://doi.org/10.1038/s41587-021-01089-xhttps://www.nature.com/articles/s41587-021-01089-x
Published Oct. 14, 2019 1:43 PM - Last modified Oct. 31, 2023 5:06 PM
E-mail this page